RE:RE:RE:BMS acquires Turning Point's TKI platform for USD$ 4.8 BlnBMS's acquisition of Turning Point's TKI platform is something ot watch since work by Lawson et al. in 2016 demonstrated that coadministration of the TKI sunitinib with reovirus could further reduce tumor burden resulting in improved survival, decreased accumulation of immune suppressor cells, and the establishment of protective immunity upon tumor rechallenge.
This could have singnificant positive implication for both BMS and ONCY, particularly since ONCY has demonstrated that pelareorep has an impactful effect on reversing a hostile tumor microenvironment (TME), making the TME more favorable to the addition of immune checkpoint inhibitors (ICIs).
Consequently, a I/O combination of ONCY's pelareorep + immune checkpoint inhibitor (ICI) + a tyrosine kinase inhibitor (TKI) could become an effective triplet in the treatment of solid tumor, such as kidney and GI cancers.